{"id":"rsd1235","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL2111112","moleculeType":"Small molecule","molecularWeight":"349.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"RSD1235 works by opening ATP-sensitive potassium channels in atrial tissue, which hyperpolarizes cardiac myocytes and increases the refractory period. This electrophysiological effect reduces the ability of ectopic foci to trigger arrhythmias and slows conduction, thereby terminating or preventing atrial fibrillation episodes. The drug's selective action on atrial tissue aims to minimize ventricular side effects.","oneSentence":"RSD1235 is a potassium channel opener that suppresses atrial fibrillation by prolonging atrial refractoriness and reducing atrial conduction velocity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:32:55.453Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation (acute conversion and prevention of recurrence)"}]},"trialDetails":[{"nctId":"NCT04485195","phase":"PHASE4","title":"RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2021-06-17","conditions":"Atrial Fibrillation","enrollment":350},{"nctId":"NCT04748991","phase":"PHASE3","title":"Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2024-09","conditions":"Atrial Fibrillation, Post-cardiac Surgery","enrollment":50},{"nctId":"NCT03005366","phase":"PHASE4","title":"Predictive Factors to Effectively Terminate Paroxysmal Atrial Fibrillation by Blocking Atrial Selective Ionic Currents","status":"COMPLETED","sponsor":"David Filgueiras-Rama","startDate":"2017-01","conditions":"Paroxysmal Atrial Fibrillation","enrollment":50},{"nctId":"NCT01370629","phase":"","title":"Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)","status":"COMPLETED","sponsor":"Correvio International Sarl","startDate":"2011-08","conditions":"Atrial Fibrillation","enrollment":2015},{"nctId":"NCT01174160","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)","status":"COMPLETED","sponsor":"Advanz Pharma","startDate":"2010-08","conditions":"Atrial Fibrillation","enrollment":123},{"nctId":"NCT01447862","phase":"PHASE4","title":"Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2011-10","conditions":"Atrial Fibrillation","enrollment":101},{"nctId":"NCT00989001","phase":"PHASE3","title":"A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)","status":"TERMINATED","sponsor":"Advanz Pharma","startDate":"2009-10","conditions":"Atrial Fibrillation","enrollment":217},{"nctId":"NCT01627106","phase":"PHASE4","title":"A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)","status":"WITHDRAWN","sponsor":"Advanz Pharma","startDate":"2012-09","conditions":"Atrial Fibrillation","enrollment":""},{"nctId":"NCT01646281","phase":"PHASE4","title":"Vernakalant Versus Flecainide: Atrial Contractility","status":"UNKNOWN","sponsor":"Maastricht University Medical Center","startDate":"2012-08","conditions":"Atrial Fibrillation","enrollment":70},{"nctId":"NCT00668759","phase":"PHASE3","title":"A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation","status":"COMPLETED","sponsor":"Advanz Pharma","startDate":"2008-04","conditions":"Atrial Fibrillation","enrollment":254},{"nctId":"NCT00526136","phase":"PHASE2","title":"Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study","status":"COMPLETED","sponsor":"Advanz Pharma","startDate":"2007-03","conditions":"Atrial Fibrillation","enrollment":735},{"nctId":"NCT00267930","phase":"PHASE2","title":"Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence","status":"COMPLETED","sponsor":"Advanz Pharma","startDate":"2005-12","conditions":"Atrial Fibrillation","enrollment":221},{"nctId":"NCT00281554","phase":"PHASE3","title":"Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2005-10","conditions":"Atrial Fibrillation","enrollment":254},{"nctId":"NCT00476112","phase":"PHASE2, PHASE3","title":"A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter","status":"COMPLETED","sponsor":"Advanz Pharma","startDate":"2003-08","conditions":"Atrial Flutter","enrollment":60},{"nctId":"NCT00468767","phase":"PHASE3","title":"Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation","status":"COMPLETED","sponsor":"Advanz Pharma","startDate":"2003-08","conditions":"Atrial Fibrillation","enrollment":356},{"nctId":"NCT00115791","phase":"PHASE3","title":"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-06","conditions":"Atrial Flutter, Atrial Fibrillation","enrollment":276},{"nctId":"NCT00125320","phase":"PHASE3","title":"Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-06","conditions":"Atrial Fibrillation, Atrial Flutter","enrollment":190}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["vernakalant","Kynapid"],"phase":"phase_3","status":"active","brandName":"RSD1235","genericName":"RSD1235","companyName":"Astellas Pharma Inc","companyId":"astellas-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RSD1235 is a potassium channel opener that suppresses atrial fibrillation by prolonging atrial refractoriness and reducing atrial conduction velocity. Used for Atrial fibrillation (acute conversion and prevention of recurrence).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}